CANbridge Pharmaceuticals Doses First Patient in CAN103 Gaucher Disease Trial
China-based rare disease firm CANbridge Pharmaceuticals announced the dosing of the first patient in a...
HKG: 2269
WuXi Biologics to Build $1.4B CRDMO Hub in Singapore, Creating 1,500 Jobs
China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced...
WuXi XDC Partners with AbTis to Advance ADC Development and Manufacturing
WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA (SHA: 603259),...
Wuxi Biologics Set to Be Removed from US Restricted Trade List
Wuxi Biologics (HKG: 2269) is reportedly on the verge of being removed from a US...
WuXi Biologics’ MFG14 Facility Approved for Microbial Product Manufacturing
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its...